The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia

Bibliography

• Dores GM, Anderson WF, Curtis RE, Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007;139:809-19
   PubMed Web of Science ®Google Scholar
• Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009;602-9
   PubMedGoogle Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009;115:2824-36
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Kontoyiannis D, Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:1755-62
   PubMed Web of Science ®Google Scholar
• Keating MJ. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-55
   PubMed Web of Science ®Google Scholar
• Lowenberg M, Verhaar AP, van den Brink GR, Hommes DW. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med 2007;13:158-63
   PubMed Web of Science ®Google Scholar
• Turner JD, Alt SR, Cao L, Transcriptional control of the glucocorticoid receptor: cpG islands, epigenetics and more. Biochem Pharmacol 2010;80:1860-8
   PubMed Web of Science ®Google Scholar
• Zhou J, Cidlowski JA. The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 2005;70:407-17
   PubMed Web of Science ®Google Scholar
• Harmon JM, Elsasser MS, Eisen LP, Glucocorticoid receptor expression in receptorless mutants isolated from the human leukemic cell line CEM-C7. Mol Endocrinol 1989;3:734-43
   PubMed Web of Science ®Google Scholar
• Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284:555-6
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Burmester GR, Brand MD. Therapeutically targeting lymphocyte energy metabolism by high-dose glucocorticoids. Biochem Pharmacol 2000;59:597-603
   PubMed Web of Science ®Google Scholar
• McColl A, Michlewska S, Dransfield I, Rossi AG. Effects of glucocorticoids on apoptosis and clearance of apoptotic cells. Sci World J 2007;7:1165-81
   Google Scholar
• Alnemri ES, Maksymowych AB, Robertson NM, Litwack G. Characterization and purification of a functional rat glucocorticoid receptor overexpressed in a baculovirus system. J Biol Chem 1991;266:3925-36
   PubMed Web of Science ®Google Scholar
• Rhee K, Bresnahan W, Hirai A, c-Myc and cyclin D3 (CcnD3) genes are independent targets for glucocorticoid inhibition of lymphoid cell proliferation. Cancer Res 1995;55:4188-95
   PubMed Web of Science ®Google Scholar
• Caron-Leslie LA, Cidlowski JA. Similar actions of glucocorticoids and calcium on the regulation of apoptosis in S49 cells. Mol Endocrinol 1991;5:1169-79
   PubMed Web of Science ®Google Scholar
• Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest 2008;134:394-401
   PubMed Web of Science ®Google Scholar
• Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ 2002;9:6-19
   PubMed Web of Science ®Google Scholar
• McColl KS, He H, Zhong H, Apoptosis induction by the glucocorticoid hormone dexamethasone and the calcium-ATPase inhibitor thapsigargin involves Bc1-2 regulated caspase activation. Mol Cell Endocrinol 1998;139:229-38
   Google Scholar
• Laane E, Panaretakis T, Pokrovskaja K, Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members. Haematologica 2007;92:1460-9
   PubMed Web of Science ®Google Scholar
• Laane E, Tamm KP, Buentke E, Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ 2009;16:1018-29
   PubMed Web of Science ®Google Scholar
• Grander D, Kharaziha P, Laane E, Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies. Autophagy 2009;5:1198-200
   PubMed Web of Science ®Google Scholar
• Johnston JB, Daeninck P, Verburg L, P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 1997;26:435-49
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-16
   PubMed Web of Science ®Google Scholar
• Zenz T, Mertens D, Dohner H, Stilgenbauer S. Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011;25:131-7
   PubMed Web of Science ®Google Scholar
• Zenz T, Mohr J, Edelmann J, Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 2009;50:510-13
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010:481-8
   PubMedGoogle Scholar
• Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol 2010;49:239-48
   PubMed Web of Science ®Google Scholar
• Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann NY Acad Sci 2004;1024:124-37
   PubMed Web of Science ®Google Scholar
• Klein NC, Go CH, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am 2001;15:423-32. viii
   PubMed Web of Science ®Google Scholar
• Pearson OH, Eliel LP, Adrenocorticotropic hormone- and cortisone-induced regression of lymphoid tumors in man; a preliminary report. Cancer 1949;2:943-5
   PubMed Web of Science ®Google Scholar
• Ezdinli EZ, Stutzman L, Aungst CW, Firat D. Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia. Cancer 1969;23:900-9
   PubMed Web of Science ®Google Scholar
• Burningham RA, Restrepo A, Pugh RP, Weekly high-dosage glucocorticosteroid treatment of lymphocytic leukemias and lymphomas. N Engl J Med 1964;270:1160-6
   PubMed Web of Science ®Google Scholar
• Han T, Ezdinli EZ, Shimaoka K, Desai DV. Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer 1973;31:502-8
   PubMed Web of Science ®Google Scholar
• Sawitsky A, Rai KR, Glidewell O, Silver RT. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977;50:1049-59
   PubMed Web of Science ®Google Scholar
• Montserrat E, Alcala A, Parody R, Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 1985;56:2369-75
   PubMed Web of Science ®Google Scholar
• Liepman M, Votaw ML. The treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer 1978;41:1664-9
   PubMed Web of Science ®Google Scholar
• Leporrier M. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319-25
   PubMed Web of Science ®Google Scholar
• Catovsky D, Fooks J, Richards S. The UK Medical Research Council CLL trials 1 and 2. Nouv Rev Fr Hematol 1988;30:423-7
   PubMedGoogle Scholar
• Keating MJ, O'Brien S, Lerner S, Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998;92:1165-71
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarjian H, Beran M, Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993;82:1695-700
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M, Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96:2723-9
   PubMed Web of Science ®Google Scholar
• Oken MM, Lee S, Kay NE, Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymphoma 2004;45:79-84
   PubMed Web of Science ®Google Scholar
• Laurencet F, Ballabeni P, Rufener B, The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas. Acta Haematol 2007;117:40-7
   PubMed Web of Science ®Google Scholar
• CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 1999;91:861-8
   PubMed Web of Science ®Google Scholar
• Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:230-9
   PubMed Web of Science ®Google Scholar
• Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010;23:47-59
   PubMed Web of Science ®Google Scholar
• Schwartz CL, Thompson EB, Gelber RD, Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol 2001;19:1040-6
   PubMed Web of Science ®Google Scholar
• Yetgin S, Tuncer MA, Cetin M, Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up. Leukemia 2003;17:328-33
   PubMed Web of Science ®Google Scholar
• Veerman AJ, Kamps WA, van den Berg H, Childhood Oncology Group. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 2009;10:957-66
   PubMed Web of Science ®Google Scholar
• Buttgereit F, da Silva JA, Boers M, Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718-22
   PubMed Web of Science ®Google Scholar
• Bosanquet AG, McCann SR, Crotty GM, Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematol 1995;93:73-9
   PubMed Web of Science ®Google Scholar
• Thornton PD, Hamblin M, Treleaven JG, High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 1999;34:167-70
   PubMed Web of Science ®Google Scholar
• Thornton PD, Matutes E, Bosanquet AG, High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003;82:759-65
   PubMed Web of Science ®Google Scholar
• Xu W, Miao KR, Hong M, High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia. Eur J Cancer 2010;46:2145-9
   PubMed Web of Science ®Google Scholar
• Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002;100:1765-73
   PubMed Web of Science ®Google Scholar
• Bowen DA, Call TG, Jenkins GD, Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48:2412-17
   PubMed Web of Science ®Google Scholar
• Dungarwalla M, Evans SO, Riley U, High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008;93(3):475-6
   PubMed Web of Science ®Google Scholar
• Castro JE, Sandoval-Sus JD, Bole J, Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048-53
   PubMed Web of Science ®Google Scholar
• Pileckyte R, Jurgutis M, Valceckiene V, Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed orrefractory high-risk chronic lymphocytic leukemia. Leuk Lymphoma 2011;52:1055-65
   PubMed Web of Science ®Google Scholar
• Hardman JG, Limbird LE. editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th edition. Mc Graw-Hill; New York: 1998
   Google Scholar
• Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;24310:1353-6
   PubMed Web of Science ®Google Scholar
• Quinn JP, Mohamedbhai S, Chipperfield K, Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia. Leuk Lymphoma 2008;49:1995-8
   PubMed Web of Science ®Google Scholar
• Castro JE, Barajas-Gamboa JS, Melo-Cardenas J, Ofatumumab and high-dose methylprednisolone is an effective salvage treatment for heavily pretreated, unfit or refractory patients with chronic lymphocytic leukemia: single institution experience. ASH Annual Meeting Abstracts 2010;116:4638
   Google Scholar
• Teichman ML, Ho VQ, Balducci L, Efficacy of ofatumumab and high-dose methylprednisolone for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 2011;118:4619
   Google Scholar
• Spaner DE. Oral high-dose glucocorticoids and Ofatumumab in fludarabine-resistant chronic lymphocytic leukemia. Leukemia 2011: [Epub ahead of print]
   PubMedGoogle Scholar
• Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006;201:441-5
   Google Scholar
• Stilgenbauer S, Cymbalista F, Leblond V, Alemtuzumab plus oral dexamethasone, followed by alemtuzumab maintenance or allogeneic transplantation in ultra high-risk CLL: interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW. ASH Annual Meeting Abstracts 2011;118:2854
   Google Scholar